Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) is expected to release its earnings data before the market opens on Friday, April 4th. Analysts expect Avalo Therapeutics to post earnings of $0.58 per share for the quarter.
Avalo Therapeutics Stock Down 5.3 %
AVTX stock traded down $0.45 on Monday, reaching $8.01. 39,379 shares of the company traded hands, compared to its average volume of 72,321. Avalo Therapeutics has a one year low of $5.99 and a one year high of $22.47. The firm has a fifty day simple moving average of $7.65 and a 200-day simple moving average of $9.14.
Analyst Ratings Changes
Several analysts recently commented on the stock. Wedbush restated an "outperform" rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research note on Thursday, March 20th. HC Wainwright reissued a "neutral" rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Jefferies Financial Group began coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They issued a "buy" rating and a $23.00 price objective for the company. Stifel Nicolaus began coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They set a "buy" rating and a $36.00 target price on the stock. Finally, BTIG Research began coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They issued a "buy" rating and a $40.00 price target for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Avalo Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $33.00.
View Our Latest Analysis on Avalo Therapeutics
Avalo Therapeutics Company Profile
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
See Also
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
